

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

Stephen M. Charme  
WITMAN STADTMAUER, P.A.  
26 Columbia Turnpike  
Florham Park, New Jersey 07932-2213  
(973) 822-0220

John M. Agnello  
Melissa E. Flax  
CARELLA, BYRNE, CECCHI,  
OLSTEIN, BRODY & AGNELLO, P.C.  
5 Becker Farm Road  
Roseland, New Jersey 07068  
(973) 994-1700

*Attorneys for Plaintiffs*

DR. FADI CHAABAN, DR. SABINO R.  
TORRE, DR. CONSTANTINOS A.  
COSTEAS, AND DR. ANTHONY J.  
CASELLA as Trustees of Diagnostic &  
Clinical Cardiology, P.A. Profit Sharing Plan,

Plaintiffs,

v.

DR. MARIO A. CRISCITO,

Defendant.

Case No. 2:08-cv-01567 (GEB/MCA)

**DECLARATION OF  
ANTHONY J. CASELLA IN  
OPPOSITION TO DEFENDANT'S  
MOTION FOR SUMMARY  
JUDGMENT**

I, Anthony J. Casella, being of full age, hereby declare as follows:

1. I have read "Defendant's Statement of Undisputed Material Facts, Pursuant to L. Civ. R. 56.1(a)", the "Declaration of Robert J. Conroy in Support of Motion for Summary Judgment Pursuant to Fed. R. Civ. P. 56" and "Defendant's Brief in Support of Motion for Summary Judgment, Pursuant to Fed. R. Civ. P. 56".

2. I am submitting this declaration in opposition to Defendant, Dr. Mario Criscito's ("Criscito") Motion for Summary Judgment.


3. The statements set forth in Paragraphs 10 and 11 of Defendant's Rule 56.1 Statement are accurate. However, my responsibility for handling the day to day financial aspects of Diagnostic & Clinical Cardiology, P.A.'s ("DCC") medical practice was dramatically reduced when new officers of DCC were elected in 2006.

4. I reported DCC employee salary and demographic information to APC from approximately 1993 to 2007. In 2007, Mark Brown, DCC's Administrator assumed responsibility for reporting DCC employee salary and demographic information to APC. The reporting of employee salary and demographic information was my only involvement with APC (other than with respect to my individual account) until Criscito was removed as sole Trustee in July 2007.

5. Annexed hereto as Exhibit 1 is a true and accurate copy of the September 30, 2010 monthly statement for the Smith Barney account showing an account value of \$771,846.06.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Executed on October 4, 2010.

  
\_\_\_\_\_  
ANTHONY J. CASELLA

# **EXHIBIT 1**

Ref: 00025391 00170053

# MorganStanley SmithBarney

## Client Statement

July 1 - September 30, 2010

Page 1 of 8

110000025391 310273AB01 WSC00064A  
 DIAGNOSTIC AND CLINICAL  
 CARDIOLOGY PA MPP 4/1/76  
 375 MOUNT PLEASANT AVENUE  
 WEST ORANGE NJ 07052-2724

Account number 416-30833-16 707  
 Morgan Stanley Smith Barney LLC. Member SIPC.  
 Your Financial Advisor  
 Allan Yarkin/ Hank Boyce  
 20807 BISCAYNE BLVD  
 6TH FLOOR  
 AVENTURA FL 33180  
 305 938 6690  
 Email: allan.d.yarkin@msb.com  
 Website: www.smithbarney.com  
 Branch Phone: 877 848 4761

Account carried by Citigroup Global Markets Inc. Member SIPC.

Account value		Last period	This period	%
Money fund		\$ 2,671.42	\$ 2,674.24	.36
Bank Deposit Program <sup>SM</sup> principal		646,914.54	646,982.81	83.82
Common stocks & options		112,044.58	122,208.01	15.83
<b>Total value</b>		<b>\$ 761,630.54</b>	<b>\$ 771,846.06</b>	<b>100.00</b>

Earnings summary		This period	This year
Money fund earnings		\$ 2.82	\$ 3.67
Bank Deposit Program <sup>SM</sup>		48.27	82.14
<b>Total</b>		<b>\$ 51.09</b>	<b>\$ 85.81</b>

Gain/loss summary		This period	This year
Realized gain or (loss)		\$ 0.00	\$ 138,915.00 LT
Unrealized gain or (loss) to date		(24,031.46)	\$ 0.00 ST

Cash, money fund, bank deposits		This period
<b>Opening balance</b>		<b>\$ 849,585.96</b>
Money fund earnings reinvested		2.82
Bank Deposit Program <sup>SM</sup> interest reinvested		48.27
<b>Closing balance</b>		<b>\$ 849,637.06</b>

Portfolio summary		This period	This year
Beginning total value (excl. accr. int.)		\$ 761,630.54	\$ 819,150.59
Net security deposits/withdrawals		0.00	0.00
Net cash deposits/withdrawals		0.00	0.00
Beginning value net of deposits/withdrawals		761,630.54	819,150.59
Total value as of 9/30/2010 (excl. accr. int.)		\$ 771,846.06	\$ 771,846.06
Change in value		\$ 10,215.52	(\$ 47,304.53)

A free credit balance in any securities account may be paid to you on demand. Although properly accounted for, these funds may be used for business purposes.

Ref: 00025391 00170054

MorganStanley  
SmithBarneyClient Statement  
July 1 - September 30, 2010

Page 2 of 8

DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

## PORTFOLIO DETAILS

Your holdings are valued using the most current prices available to Citigroup Global Markets Inc. (CGMI). In most cases, these values are as of 09/30/10, but in some cases CGMI's sources are unable to provide timely information. To see the date of the most recent price update, please view your account online at [www.smithbarney.com](http://www.smithbarney.com).

Securities purchased or sold are included or excluded in this section as of the trade date. This section may include securities that have not settled as of this statement closing date. Please see the "Unsettled Purchases/Sales" section for more information. Dividend yield is the estimated annual income, assuming the current dividend, divided by the security's market price at the end of the statement period. We do not guarantee the accuracy of the prices reflected on the statement nor do these prices represent levels at which securities can be bought or sold.

**Please Note:** unrealized gain/(loss) is being shown for informational purposes only and should not be used for tax preparation without the assistance of your tax advisor.

## Money fund

An investment in a money market fund is neither insured nor guaranteed by the FDIC or any other government agency. Although money market funds seek to preserve the value of your investment at \$1.00 per share, there can be no assurance that will occur and it is possible to lose money should the fund value per share fall. Moreover, in some circumstances money market funds may be forced to cease operations when the value of a fund drops below \$1.00 per share. In that event, the fund's holdings would be liquidated and distributed to the fund's shareholders. This liquidation process could take up to one month or more. During that time, these funds would not be available to you to support purchases, withdrawals, and if applicable, check writing or ATM debits from your account.

Number of shares	Description	Current value	Accrued dividends	Annualized % dividend yield	Anticipated income (annualized)
2,674.24	WESTERN ASSET MONEY MARKET FUND CLASS A	\$ 2,674.24		.06 %	\$ 1.60
Total money fund		\$ 2,674.24	\$ 0.00	.06 %	\$ 1.60

## Bank Deposit Program

The Federal Deposit Insurance Corporation (FDIC) provides insurance on deposits up to \$250,000 per account owner, per bank. However, the Smith Barney Bank Deposit Program (BDP) applies certain limits to the maximum deposit amount permitted in certain banks, which may be below the maximum FDIC insurance limits for certain types of accounts. In those instances where an account type exceeds the maximum FDIC insurance limits, those deposits will be uninsured. Balances maintained in Deposit Accounts at each Affiliated Program Bank are not protected by the Securities Investor Protection Corporation ("SIPC") or any excess-SIPC coverage provided by Citigroup Global Markets Inc. For complete details please refer to the "Bank Deposit Program Disclosure Statement."

Principal	Description	Current value	Accrued interest	Annualized % return	Anticipated income (annualized)
149,950.71	CITIBANK NA BANK DEPOSIT PROGRAM	\$ 149,950.71		.03 %	\$ 44.98
248,506.05	CITICORP TRUST BANK, FSB	\$ 248,506.05		.03 %	\$ 74.55

Ref: 00025391 00170055

MorganStanley  
SmithBarneyClient Statement  
July 1 - September 30, 2010

Page 3 of 8

## DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

Bank Deposit Program *continued*

Principal	Description	Current value	Accrued interest	Annualized % return	Anticipated income (annualized)
248,506.06	CITIBANK NA SOUTH DAKOTA BANK DEPOSIT PROGRAM	\$ 248,506.06		.03 %	\$ 74.55
Total Bank Deposit Program		\$ 248,506.06	\$ 0.00	.03 %	\$ 74.55

## Common stocks &amp; options

Citi Investment Research & Analysis (CIRA), Morgan Stanley & Co. Incorporated (Morgan Stanley) and Standard & Poor's research ratings may be shown for certain securities. All research ratings represent the "opinions" of the research provider and are not representations or guarantees of performance. Because the research report contains more complete information regarding the analyst's opinions, analysis, and rating, you should read the entire research report and not infer its contents from the rating. Where a particular company is covered by both CIRA and Morgan Stanley, you can and should view both research reports. CIRA and Morgan Stanley research reports may contain different or conflicting information about the subject companies of such research reports because they are prepared separately from each other. CIRA stock recommendations include an investment rating and a risk rating. The Investment Rating Code (1, 2 or 3) is a function of CIRA's expectation of total return (forecast price appreciation and dividend yield within the next twelve months) and a Risk Rating. The Risk Rating (L, M, H or S) represents the stock's expected risk, taking into account price volatility and fundamental criteria. Please refer to the end of this statement for a guide describing CIRA ratings. Morgan Stanley and Standard & Poor's research ratings have been normalized by these providers to a 1 (Buy), 2 (Hold), and 3 (Sell). Morgan Stanley Smith Barney is not the author of, does not take responsibility for, and does not guarantee the accuracy, completeness, or timeliness of research prepared by Standard & Poor's.

Quantity	Description	Symbol	Date acquired	Cost	Share cost	Current price	Current value	Unrealized gain/(loss)	Average % yield	Anticipated income (annualized)
96.371	ALCATEL-LUCENT ADR	ALU	01/27/99	\$ 19,994.71	\$ 207.896	\$ 3.38	\$ 325.73	(\$ 19,668.98)		
54.6103	Rating: Citigroup : 1H Morgan Stanley : 2 S&P : 2		01/27/99	11,342.44	208.108	3.38	184.58	(11,157.86)		
2.7082	Reinvestments to date			118.71	43.096	3.38	9.15	(107.56)		
153.6896				31,453.86	204.858		519.46	(30,934.40)		
27.2629	LSI CORP	LSI	01/27/99	3,988.78	148.914	4.56	124.05	(3,862.73)		
15.449	Rating: Morgan Stanley : 2 S&P : 2		01/27/99	2,261.59	147.071	4.56	70.29	(2,191.30)		
2881	Reinvestments to date			18.46	64.074	4.56	1.31	(17.15)		
43				0,286.83	145.74		186.65	(6,071.18)		
8.030	SYMANTEC CORP	SYM	01/14/99	108,519.78	13.514	15.13	121,493.90	12,974.12		
	Rating: Citigroup : 2M Morgan Stanley : 2 S&P : 2									
Total common stocks and options				\$ 146,240.47			\$ 122,208.01	\$ 0.00 ST	0.00	\$ 0.00
Total portfolio value				\$ 796,877.52			\$ 771,848.06	\$ 0.00 ST	.02	\$ 186.58
								(\$ 24,031.46) LT		

Ref: 00025391 00170056

MorganStanley  
SmithBarneyClient Statement  
July 1 - September 30, 2010

Page 4 of 8

DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

**EARNINGS DETAILS***The tax status of earnings is reliable to the best of our knowledge. Taxable and non-taxable designations refer to the federal income tax status of your securities, not of your account.***Money fund earnings**

Date	Description	Comment	Taxable	Non-taxable	Amount
07/30/10	WESTERN ASSET MONEY MARKET FUND CLASS A	REINVESTED FOR PERIOD 07/01/10-08/01/10 32 DAYS AVERAGE YIELD 1.06 %.	\$ 2.37		\$ 2.37
08/31/10	WESTERN ASSET MONEY MARKET FUND CLASS A	REINVESTED FOR PERIOD 08/02/10-08/31/10 30 DAYS AVERAGE YIELD .20 %.	.40		.40
09/30/10	WESTERN ASSET MONEY MARKET FUND CLASS A	REINVESTED FOR PERIOD 09/01/10-09/30/10 30 DAYS AVERAGE YIELD .06 %.	.05		.05
<b>Total earnings from money fund</b>			<b>\$ 2.82</b>	<b>\$ 0.00</b>	<b>\$ 2.82</b>

**Bank Deposit Program™ interest***This section contains interest credited to your account. Accrued interest is not included. See Portfolio details section for accrued interest information.*

Date	Description	Comment	Taxable	Non-taxable	Amount
07/30/10	CITIBANK NA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 07/01/10-08/01/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	\$ 3.89		\$ 3.89
07/30/10	CITIBANK NA SOUTH DAKOTA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 07/01/10-08/01/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	6.46		6.46
07/30/10	CITICORP TRUST BANK, FSB	REINVESTED FOR PERIOD 07/01/10-08/01/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	6.46		6.46
08/31/10	CITIBANK NA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 08/02/10-08/31/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	3.64		3.64
08/31/10	CITIBANK NA SOUTH DAKOTA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 08/02/10-08/31/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	6.04		6.04
08/31/10	CITICORP TRUST BANK, FSB	REINVESTED FOR PERIOD 08/02/10-08/31/10 INTEREST RATE AS OF THE STATEMENT END DATE .03 %.	6.04		6.04

Ref: 00025391 00170057

MorganStanley  
SmithBarney

## Client Statement

July 1 - September 30, 2010

Page 5 of 8

## DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

Bank Deposit Program<sup>SM</sup> Interest continued

This section contains interest credited to your account. Accrued interest is not included. See Portfolio details section for accrued interest information.

Date	Description	Comment	Taxable	Non-taxable	Amount
09/30/10	CITIBANK NA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 09/01/10-09/30/10 INTEREST RATE AS OF THE STATEMENT END DATE .03%	\$ 3.64		\$ 3.64
09/30/10	CITIBANK NA SOUTH DAKOTA BANK DEPOSIT PROGRAM	REINVESTED FOR PERIOD 09/01/10-09/30/10 INTEREST RATE AS OF THE STATEMENT END DATE .03%		6.05	6.05
09/30/10	CITICORP TRUST BANK, FSB	REINVESTED FOR PERIOD 09/01/10-09/30/10 INTEREST RATE AS OF THE STATEMENT END DATE .03%		6.05	6.05
Total Bank Deposit Program Interest earned			\$ 48.27	\$ 0.00	\$ 48.27

## GAIN/LOSS DETAILS

Please note, this material is being prepared for informational purposes only and should not be used for tax preparation without the assistance of your tax advisor. Absent specific instructions from you, trades are allocated using the FIFO (first-in/first-out) method. Day traders should therefore not rely on this section for day trading results. Your reinvestment activity has been summarized. Single lines have been designated to distinguish Short-term (ST) or Long-term (LT) information. Detailed information will be available at year-end in your 1099 Year-end summary.

## Realized gain or loss

Description	Original trade date	Closing trade date	Quantity	Purchase price	Sale price	Cost basis	Proceeds	Realized gain or (loss)
SYMANTEC CORP CGM AND/OR ITS AFFILIATES FIGURED TO S/D 04-15-10 TRADE AS OF 04/12/10	01/14/99	04/12/10 Sold	10,000	\$ 13.514	\$ 17.163	\$ 135,142.94	\$ 171,022.10	\$ 35,879.16 LT
SYMANTEC CORP CGM AND/OR ITS AFFILIATES	01/14/99	04/22/10 Sold	8,000	13.514	17.21	108,114.35	137,271.67	29,157.32 LT
SYMANTEC CORP CGM AND/OR ITS AFFILIATES	01/14/99	04/22/10 Sold	2,000	13.514	17.20	27,028.59	34,299.41	7,270.82 LT
SYMANTEC CORP CGM AND/OR ITS AFFILIATES	01/14/99	04/23/10 Sold	10,000	13.514	17.35	135,142.94	172,991.06	37,848.12 LT



Ref: 00025391 00170058

MorganStanley  
SmithBarney

Page 6 of 8

## Client Statement

July 1 - September 30, 2010

DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

Realized gain or loss *continued*

Description	Original trade date	Closing trade date	Quantity	Purchase price	Sale price	Cost basis	Proceeds	Realized gain or (loss)
SYMANTEC CORP CGM AND/OR ITS AFFILIATES	01/14/99	04/28/10 Sold	7,500	\$ 13.514	\$ 17.40	\$ 101,357.21	\$ 130,116.79	\$ 28,759.58 LT
<b>Total</b>			<b>37,500</b>			<b>\$ 606,786.03</b>	<b>\$ 646,701.03</b>	<b>\$ 138,915.00</b>
<b>Total realized gain or (loss) - this period</b>						<b>\$ 0.00</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>
<b>Total Long Term - year-to-date</b>								<b>\$ 138,915.00</b>
<b>Total Short Term - year-to-date</b>								<b>\$ 0.00</b>
<b>Total realized gain or (loss) - year-to-date</b>						<b>\$ 606,786.03</b>	<b>\$ 646,701.03</b>	<b>\$ 138,915.00</b>

Ref: 00025391 00170059

# MorganStanley SmithBarney

## Client Statement

July 1 - September 30, 2010

Page 7 of 8

### Guide to Citi Investment Research & Analysis (CIRA) Investment Ratings

DIAGNOSTIC AND CLINICAL

Account number 416-30833-16 707

#### Stock Ratings

Investment ratings are based upon CIRA's expectation of total return (forecast price appreciation plus dividend yield within the next 12 months) and risk rating.

Developed Markets (US, UK, Europe, Japan, and Australia/New Zealand)

Code	Rating	Expected Total Return
1	Buy	10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks
2	Hold	0-10% for Low-Risk stocks, 0-15% for Medium-Risk stocks, 0-20% for High-Risk stocks, and 0-35% for Speculative stocks
3	Sell	Negative total return

#### Stock Risk

Takes into account price volatility and a select list of fundamental criteria.

Code	Rating	Definitions
L	Low	High predictability of financial results and low volatility
M	Medium	Moderate predictability of financial results and volatility
H	High	Low predictability of financial results and high volatility
S	Speculative	Exceptionally low financial predictability, highest risk and volatility

#### Morgan Stanley Stock Ratings

Morgan Stanley's ratings system differs from the CIRA rating system. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks they cover. Their ratings, Overweight, Equal-weight, Not-Rated and Underweight, are not the equivalent of Buy, Hold, and Sell, but represent recommended relative weightings. To satisfy regulatory requirements, Morgan Stanley corresponds Overweight, their most positive stock rating, with a Buy (1) recommendation, they correspond Equal-weight and Not-Rated to Hold (2) and Underweight to Sell (3) recommendations, respectively. These corresponding ratings are displayed on account statements. Morgan Stanley's own proprietary ratings, shown below, are displayed on Morgan Stanley research reports:

Code	Rating	Definition
O	Overweight	The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
E	Equal-weight	The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
NR	Not-Rated	Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
U	Underweight	The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
NA, NA or **	appearing for Morgan Stanley Research indicates that the ratings for this company are not available because of a Morgan Stanley policy.	

#### Message: Consolidated Statement of Financial Condition:

At June 30, 2010, Citigroup Global Markets Inc. had net capital of \$8.31 billion which exceeded the Securities and Exchange Commission's minimum requirement by \$7.56 billion. A copy of the Citigroup Global Markets Inc. Consolidated Statement of Financial Condition can be viewed online at: [www.smithbarney.com/pdf/sfc2436.pdf](http://www.smithbarney.com/pdf/sfc2436.pdf) or may be mailed to you at no cost by calling (877) 936-2737.

Ref: 00025391 00170090

**MorganStanley  
SmithBarney**

Page 8 of 8

**Client Statement**  
July 1 - September 30, 2010

**DIAGNOSTIC AND CLINICAL**

**Account number 416-30833-16 707**

**Message: Important Information If you are a margin customer**

*If you have a margin account with us, as permitted by law we may use certain securities in your account for, among other things, settling short sales and lending the securities for short sales, and as a result may receive compensation in connection therewith.*

*Information regarding commissions and charges will be made available to you promptly upon request. Please advise Morgan Stanley Smith Barney of any material change in your financial objectives or financial situation. All checks written and deposited to your account must be made payable to Citigroup Global Markets Inc. A financial statement of Citigroup Global Markets Inc. is available for your personal inspection at its offices, or a copy of it will be mailed upon your written request. If you believe there are any inaccuracies or discrepancies in your account, you must promptly contact Citigroup Global Markets Inc. at 212-723-9903 and the Manager of the branch servicing your account (see page 1 of statement for address and phone number). To protect your rights, including any rights you may have under the Securities Investor Protection Act (SIPA), you should reconfirm all oral communication in writing to Morgan Stanley Smith Barney, Attention: Early Dispute Resolution Group, 485 Lexington Avenue, 14th Floor, New York, NY 10017.*